Lung Cancer Research

As one of the world's largest cancer research centers, MD Anderson is leading the investigation into new methods of lung cancer diagnosis and treatment. Each patient benefits from the most advanced research, delivered as rapidly as possible.

Our current lung cancer research efforts include:

• Playing a leading role in the innovative Lung-MAP study – an umbrella clinical trial program that uses genomic screening to guide patients with advanced-stage SCC to the most beneficial targeted therapy or immunotherapy clinical trial
• The continued validation of aggressive local treatment – such as surgery, radiation therapy or both – following chemotherapy treatment for NSCLC
• An alliance with Bristol-Myers Squibb in an effort to extend the benefits of immunotherapy to all patients, including those with early-stage lung cancer
• Two ongoing clinical trials examining the effectiveness of PARP inhibitors in the treatment of SCLC
• Profiling 100 surgically resected early-stage tumors in an effort to define the baseline immune characteristics of patients with NSCLC through the ICON project
• Preclinical study evidence supporting clinical testing of poziotinib to treat NSCLC patients with EGFR and HER2 exon 20 insertions
• A partnership with Adaptimmune, LLC to develop novel T cell therapies for NSCLC, enabling a currently open Phase I trial for MAGE-A10 positive head or neck tumors
• Clinical trials to determine the effectiveness of specific therapies for each KRAS-mutant subtype of NSCLC, including a currently open Phase I trial examining the ability of CB-839 to treat the KL subtype of KRAS-driven NSCLC
• An open Phase I trial testing the effectiveness of an investigational immunotherapy, GSK3174998, in treating advanced solid tumors (recurring or metastatic), including NSCLC